PSNL RSI Chart
Last 7 days
-10.8%
Last 30 days
16.7%
Last 90 days
2.9%
Trailing 12 Months
-30.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 74.1M | 0 | 0 | 0 |
2023 | 68.7M | 67.1M | 70.5M | 73.5M |
2022 | 79.8M | 76.4M | 69.0M | 65.0M |
2021 | 80.4M | 82.5M | 85.0M | 85.5M |
2020 | 70.3M | 74.0M | 76.6M | 78.6M |
2019 | 47.7M | 54.7M | 60.2M | 65.2M |
2018 | 16.5M | 23.6M | 30.7M | 37.8M |
2017 | 0 | 0 | 0 | 9.4M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 30, 2024 | moore stephen michael | sold | -6,196 | 1.37 | -4,523 | svp and chief legal officer |
Mar 01, 2024 | myers woodrow a jr | bought | 16,700 | 1.67 | 10,000 | - |
Jan 29, 2024 | chen richard | sold | -720 | 1.37 | -526 | chief medical officer and evp |
Jan 29, 2024 | tachibana aaron | sold | -980 | 1.37 | -716 | cfo and coo |
Dec 15, 2023 | tachibana aaron | sold | -9,918 | 1.47 | -6,747 | cfo and coo |
Dec 15, 2023 | moore stephen michael | sold | -2,169 | 1.47 | -1,476 | general counsel |
Dec 15, 2023 | chen richard | sold | -6,920 | 1.47 | -4,708 | chief medical officer and evp |
Nov 16, 2023 | chen richard | sold | -977 | 1.04 | -940 | chief medical officer and evp |
Nov 16, 2023 | tachibana aaron | sold | -1,397 | 1.04 | -1,344 | cfo and coo |
Nov 16, 2023 | moore stephen michael | sold | -1,790 | 1.04 | -1,722 | general counsel |
Which funds bought or sold PSNL recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | COMERICA BANK | unchanged | - | -172 | 422 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | added | 226 | 53,867 | 94,691 | -% |
May 15, 2024 | Man Group plc | added | 416 | 316,598 | 435,332 | -% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | added | 4.71 | -69,906 | 202,044 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | reduced | -12.42 | -212,216 | 348,268 | -% |
May 15, 2024 | Board of Trustees of The Leland Stanford Junior University | reduced | -14.28 | -18,188 | 28,232 | -% |
May 15, 2024 | MARSHALL WACE, LLP | added | 39.04 | -4,286 | 314,244 | -% |
May 15, 2024 | TWO SIGMA ADVISERS, LP | reduced | -1.32 | -66,929 | 156,301 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | new | - | 37,289 | 37,289 | -% |
May 15, 2024 | HOYLECOHEN, LLC | unchanged | - | -9,378 | 22,906 | -% |
Unveiling Personalis Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Personalis Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
DHR | 196.9B | 23.7B | 44.73 | 8.29 | ||||
A | 45.2B | 6.7B | 36.57 | 6.71 | ||||
IDXX | 44.9B | 3.7B | 51.83 | 12.06 | ||||
DGX | 16.0B | 9.3B | 18.95 | 1.73 | ||||
NTRA | 13.1B | 1.2B | -35.76 | 10.81 | ||||
MEDP | 12.2B | 2.0B | 38.94 | 6.2 | ||||
CRL | 11.4B | 4.1B | 26.02 | 2.78 | ||||
EXAS | 9.3B | 2.5B | -38.69 | 3.67 | ||||
MID-CAP | ||||||||
GH | 3.1B | 603.7M | -6.73 | 5.14 | ||||
NEOG | 2.9B | 929.2M | 1.9K | 3.16 | ||||
SMALL-CAP | ||||||||
CDNA | 808.3M | 275.1M | -4.41 | 2.94 | ||||
ACRS | 84.8M | 31.1M | -1.1 | 2.73 | ||||
AWH | 33.0M | 9.2M | -2.24 | 3.6 | ||||
APDN | 2.5M | 5.5M | -0.2 | 0.45 | ||||
BIOC | 183.8K | 25.9M | -0.01 | 0.01 |
Personalis Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -0.8% | 19,525,000 | 19,675,000 | 18,247,000 | 16,699,000 | 18,860,000 | 16,722,000 | 14,858,000 | 18,240,000 | 15,227,000 | 20,682,000 | 22,261,000 | 21,670,000 | 20,881,000 | 20,176,000 | 19,816,000 | 19,495,000 | 19,161,000 | 18,154,000 | 17,153,000 | 15,825,000 | 14,075,000 |
Cost Of Revenue | -3.0% | 14,032,000 | 14,470,000 | 14,766,000 | 11,907,000 | 14,130,000 | 14,410,000 | 12,379,000 | 13,959,000 | 10,949,000 | 12,686,000 | 14,195,000 | 13,502,000 | 13,454,000 | 14,106,000 | 14,483,000 | 14,823,000 | 15,122,000 | 11,589,000 | 11,524,000 | 9,923,000 | 10,091,000 |
Costs and Expenses | -12.0% | 38,405,000 | 43,647,000 | 49,040,000 | 42,045,000 | 48,685,000 | 48,807,000 | 42,117,000 | 46,121,000 | 43,533,000 | 40,907,000 | 39,952,000 | 36,617,000 | 33,371,000 | 33,546,000 | 29,469,000 | 28,993,000 | 28,786,000 | 25,350,000 | 22,883,000 | 19,886,000 | 19,506,000 |
S&GA Expenses | 0.7% | 11,602,000 | 11,524,000 | 11,971,000 | 12,134,000 | 14,097,000 | 17,828,000 | 14,781,000 | 15,874,000 | 15,486,000 | 13,709,000 | 12,140,000 | 11,428,000 | 10,421,000 | 10,920,000 | 7,793,000 | 7,705,000 | 7,274,000 | 6,388,000 | 6,056,000 | 5,466,000 | 4,170,000 |
R&D Expenses | -6.2% | 12,771,000 | 13,613,000 | 16,738,000 | 17,852,000 | 16,573,000 | 16,569,000 | 14,957,000 | 16,288,000 | 17,098,000 | 14,512,000 | 13,617,000 | 11,687,000 | 9,496,000 | 8,520,000 | 7,193,000 | 6,465,000 | 6,390,000 | 7,373,000 | 5,303,000 | 4,497,000 | 5,245,000 |
EBITDA Margin | 17.0% | -1.09 | -1.32 | -1.44 | -1.48 | -1.52 | -1.61 | -1.38 | -1.13 | -0.93 | -0.69 | -0.62 | -0.54 | - | - | - | - | - | - | - | - | - |
Interest Expenses | 0% | 9,000 | 9,000 | 15,000 | 39,000 | 47,000 | 47,000 | 45,000 | 50,000 | 59,000 | 59,000 | 60,000 | 65,000 | - | - | - | - | 2,000 | - | 204,000 | 745,000 | 184,000 |
Income Taxes | 40.0% | 7,000 | 5,000 | 28,000 | 36,000 | 14,000 | 8,000 | 11,000 | 14,000 | 7,000 | -3,000 | 12,000 | 8,000 | -3,000 | 18,000 | 5,000 | 4,000 | 30,000 | 4,000 | 1,000 | 2,000 | 2,000 |
Earnings Before Taxes | 51.2% | -12,961,000 | -26,579,000 | -29,070,000 | -23,919,000 | -28,645,000 | -31,060,000 | -26,481,000 | -27,532,000 | -28,202,000 | -20,202,000 | -17,658,000 | -14,945,000 | -12,407,000 | -13,323,000 | -9,540,000 | -9,251,000 | -9,109,000 | -6,641,000 | -6,884,000 | -5,867,000 | -5,683,000 |
EBT Margin | 15.3% | -1.25 | -1.47 | -1.60 | -1.64 | -1.66 | -1.74 | -1.48 | -1.22 | -1.01 | -0.76 | -0.69 | -0.61 | - | - | - | - | - | - | - | - | - |
Net Income | 51.2% | -12,968,000 | -26,584,000 | -29,098,000 | -23,955,000 | -28,659,000 | -31,068,000 | -26,492,000 | -27,546,000 | -28,209,000 | -20,199,000 | -17,670,000 | -14,953,000 | -12,404,000 | -13,341,000 | -9,545,000 | -9,255,000 | -9,139,000 | -6,645,000 | -6,885,000 | -5,869,000 | -5,685,000 |
Net Income Margin | 15.3% | -1.25 | -1.47 | -1.60 | -1.64 | -1.66 | -1.74 | -1.48 | -1.23 | -1.01 | -0.76 | -0.69 | -0.61 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -21.1% | -20,517,000 | -16,942,000 | -17,549,000 | -13,155,000 | -19,523,000 | -26,300,000 | -36,179,000 | -37,659,000 | -19,991,000 | -18,851,000 | -20,842,000 | -30,036,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2018Q4 |
Assets | -13.2% | 195 | 225 | 227 | 249 | 272 | 293 | 318 | 358 | 381 | 397 | 407 | 383 | 396 | 245 | 249 | 146 | 152 | 157 | 160 | 192 | 42.00 |
Current Assets | -17.9% | 120 | 147 | 148 | 161 | 183 | 200 | 222 | 260 | 294 | 318 | 329 | 354 | 373 | 221 | 224 | 120 | 135 | 140 | 140 | 176 | 30.00 |
Cash Equivalents | -22.8% | 44.00 | 57.00 | 72.00 | 97.00 | 87.00 | 89.00 | 84.00 | 87.00 | 92.00 | 106 | 80.00 | 70.00 | 137 | 69.00 | 133 | 25.00 | 47.00 | 55.00 | 87.00 | 163 | 20.00 |
Net PPE | -4.9% | 55.00 | 57.00 | 57.00 | 59.00 | 61.00 | 62.00 | 61.00 | 48.00 | 31.00 | 20.00 | 18.00 | 14.00 | 11.00 | 12.00 | 13.00 | 13.00 | 13.00 | 14.00 | 15.00 | 13.00 | 11.00 |
Liabilities | -22.0% | 75.00 | 96.00 | 75.00 | 73.00 | 79.00 | 75.00 | 75.00 | 93.00 | 94.00 | 86.00 | 81.00 | 45.00 | 47.00 | 50.00 | 45.00 | 52.00 | 53.00 | 51.00 | 48.00 | 75.00 | 59.00 |
Current Liabilities | -33.6% | 31.00 | 47.00 | 32.00 | 29.00 | 34.00 | 33.00 | 34.00 | 42.00 | 40.00 | 31.00 | 27.00 | 34.00 | 39.00 | 41.00 | 36.00 | 43.00 | 52.00 | 50.00 | 47.00 | 56.00 | 58.00 |
Shareholder's Equity | -6.8% | 121 | 129 | 151 | 176 | 194 | 218 | 242 | 265 | 287 | 310 | 325 | 339 | 348 | 195 | 204 | 93.00 | 99.00 | 107 | 111 | 117 | - |
Retained Earnings | -2.8% | -481 | -468 | -442 | -413 | -389 | -360 | -329 | -302 | -275 | -247 | -226 | -209 | -194 | -181 | -168 | -158 | -149 | -140 | -133 | -127 | -115 |
Additional Paid-In Capital | 0.7% | 602 | 598 | 594 | 589 | 583 | 579 | 573 | 569 | 563 | 558 | 552 | 548 | 543 | 377 | 372 | 252 | 249 | 247 | 245 | 244 | 9.00 |
Shares Outstanding | 1.8% | 51.00 | 50.00 | 49.00 | 49.00 | 47.00 | 47.00 | 46.00 | 46.00 | 45.00 | 44.00 | 44.00 | 43.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 90,600 | - | - | - | 156 | - | - | - | 900 | - | - | - | 248 | - | - | - | 513 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -52.1% | -20,413 | -13,418 | -16,681 | -10,414 | -15,745 | -16,762 | -14,765 | -27,349 | -11,357 | -15,274 | -17,880 | -25,931 | -11,743 | -2,532 | -16,124 | -15,354 | -8,643 | 2,405 | -9,638 | -10,902 | 66.00 |
Share Based Compensation | -20.7% | 2,687 | 3,389 | 3,482 | 3,485 | 3,695 | 5,787 | 4,415 | 4,415 | 4,816 | 4,032 | 3,689 | 3,600 | 3,057 | 3,477 | 1,690 | 1,822 | 1,249 | 1,201 | 1,402 | 1,646 | 609 |
Cashflow From Investing | 154.1% | 6,301 | -11,638 | -8,605 | 19,549 | 13,793 | 21,851 | 10,826 | 23,021 | -3,161 | 39,911 | 29,669 | -47,105 | -82,544 | -63,140 | 5,647 | -7,615 | -35.00 | -34,848 | -43,930 | -1,841 | -960 |
Cashflow From Financing | -88.5% | 1,129 | 9,816 | 290 | - | - | 511 | 760 | -420 | 515 | 1,347 | -506 | 6,010 | 162,849 | 941 | 118,683 | 1,321 | 323 | 471 | -22,686 | 142,777 | 14,386 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Revenue | $ 19,525 | $ 18,860 |
Costs and expenses | ||
Cost of revenue | 14,032 | 14,130 |
Research and development | 12,771 | 16,573 |
Selling, general and administrative | 11,602 | 14,097 |
Restructuring and other charges | 3,885 | |
Total costs and expenses | 38,405 | 48,685 |
Loss from operations | (18,880) | (29,825) |
Interest income | 1,359 | 1,253 |
Interest expense | (9) | (47) |
Other income (expense), net | 4,569 | (26) |
Loss before income taxes | (12,961) | (28,645) |
Provision for income taxes | 7 | 14 |
Net loss | $ (12,968) | $ (28,659) |
Net loss per share, basic | $ (0.26) | $ (0.61) |
Net loss per share, diluted | $ (0.26) | $ (0.61) |
Weighted-average shares outstanding, basic | 50,678,586 | 46,740,270 |
Weighted-average shares outstanding, diluted | 50,678,586 | 46,740,270 |
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 43,981 | $ 56,984 |
Short-term investments | 51,438 | 57,195 |
Accounts receivable, net | 11,345 | 17,730 |
Inventory and other deferred costs | 8,767 | 10,474 |
Prepaid expenses and other current assets | 4,908 | 4,361 |
Total current assets | 120,439 | 146,744 |
Property and equipment, net | 54,529 | 57,366 |
Operating lease right-of-use assets | 17,515 | 17,852 |
Other long-term assets | 2,793 | 3,137 |
Total assets | 195,276 | 225,099 |
Current liabilities | ||
Accounts payable | 9,179 | 14,920 |
Accrued and other current liabilities | 16,159 | 23,941 |
Contract liabilities | 3,526 | 3,288 |
Short-term warrant liability | 2,509 | 5,085 |
Total current liabilities | 31,373 | 47,234 |
Long-term operating lease liabilities | 37,434 | 38,321 |
Long-term warrant liability | 2,753 | 4,942 |
Other long-term liabilities | 3,022 | 5,161 |
Total liabilities | 74,582 | 95,658 |
Commitments and contingencies (Note 11) | ||
Stockholders’ equity | ||
Common stock, $0.0001 par value - 200,000,000 shares authorized; 51,394,199 and 50,480,694 shares issued and outstanding, respectively | 5 | 5 |
Additional paid-in capital | 602,488 | 598,364 |
Accumulated other comprehensive loss | (125) | (222) |
Accumulated deficit | (481,674) | (468,706) |
Total stockholders’ equity | 120,694 | 129,441 |
Total liabilities and stockholders’ equity | $ 195,276 | $ 225,099 |